Last updated on April 2017

ALXN1210 Versus Eculizumab in Complement Inhibitor Treatment-Na ve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)


Brief description of study

The purpose of this study is to assess ALXN1210 compared to eculizumab in adult patients with PNH who have not previously used a complement inhibitor.

Clinical Study Identifier: NCT02946463

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Alexion Pharmaceuticals, Email for Complete ...

Clinical Trial Site
Whittier, CA United States
  Connect »

Alexion Pharmaceuticals, Email for Complete ...

Clinical Trial Site
Medellín, Colombia
  Connect »

Alexion Pharmaceuticals, Email for Complete ...

Clinical Trial Site
Montpellier, France
  Connect »